Navigation Links
Actavis Receives Approval of Generic Wellbutrin XL(R) 300mg in the U.S.
Date:8/18/2008

MORRISTOWN, N.J., Aug. 18 /PRNewswire/ -- Actavis Group, the international generic pharmaceuticals company, today announced that it has received approval from the U.S. Food & Drug Administration to market Bupropion Hydrochloride extended-release tablets (XL) 300mg. Distribution of the product will commence immediately.

Bupropion Hydrochloride extended-release tablets (XL), available in 300mg strength, are the generic equivalent of Wellbutrin XL(R) for the treatment of major depressive disorder. Annual US sales of brand and generic Wellbutrin XL(R) 300mg were US$581 million for the 12 months ending June 2008 according to IMS Health data.

Commenting on the new approval, Douglas Boothe, Chief Executive Officer of Actavis, Inc. said:

"Bupropion XL compliments our existing Buproprion SR offerings and expands the dosage options for our customers and patients. This approval also highlights Actavis Group's focus and expertise in bringing complex controlled-release technologies to the marketplace."

About Actavis

Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. With headquarters in Iceland, Actavis has operations in 40 countries, with 11,000 employees. The United States is the company's single largest market. Actavis' U.S. operations are located in New Jersey, Maryland, North Carolina and Florida.

More information about Actavis in the United States can be found at http://www.actavis.us.

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis. By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability.


'/>"/>
SOURCE Actavis Group
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Harvard Business School Publishes a Case Study on Robert Wessman and Actavis
2. Actavis Extends Portfolio With Four New Products in the U.S.
3. Actavis Confirms its Patent Challenge of Kings Avinza(R)
4. Actavis Launches Amlodipine Tablets in the U.S.
5. Actavis Launches Carvedilol Tablets in the U.S.
6. New probe to detect skin cancer receives more funding for clinical trials
7. NUCRYST Receives Deficiency Notice from NASDAQ
8. Dr. Ajrawats Air-Pulse Autonomic Meditation Therapy, a Revolutionary, Scientific, Meditation Therapy, Receives Patent Trademark
9. PathNet Esoteric Laboratory Institute Main Laboratory Receives Accreditation From College of American Pathologists
10. Duska Therapeutics Receives Comments From FDA on Phase 3 ATPace(TM) Protocol Synopsis
11. Morris Animal Foundation Receives $1 Million Donation From Hills for Cat Health Research - Cat Lovers Have Reason to Celebrate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... In ... a mother and divorcee, shares her enthusiasm for Botox and lip injections, which she ... world famous youth oriented Coachella Valley Music and Arts Festival. The article explains that ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... , announces the addition Onnit brand Alpha BRAIN and New Mood Daily-Stress Formula ... brain and mood optimization products to the store is just one more way ...
(Date:4/29/2016)... ... April 29, 2016 , ... The American workforce ... stability, even security. Most importantly, employees are the single most important asset in ... workers so unhappy? , Just under half of American workers are emotionally checked ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Conditions were ... at Cove Island Park on Sunday, with sunny skies, a light breeze and temperatures ... nearly $33,000. , The 5k Run and Walk and 1-mile walk were ...
(Date:4/29/2016)... ... ... Spine Team Texas, a comprehensive spine physician group specializing in the treatment of ... invited to be a featured speaker at the Texas Society of the American College ... , Dr. R. Scott McPherson, a physical medicine and rehabilitation specialist, will speak ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... Switzerland , April 27, 2016 ... AG announced the launch of a Phase 2 clinical ... residual hearing in patients undergoing cochlear implantation (CI) surgery. ... recruiting patients in Germany and ... into the middle ear at the time of surgery. ...
(Date:4/26/2016)... 26, 2016 Hill-Rom Holdings, Inc. (NYSE: ... at the Deutsche Bank 41 st Annual Health Care ... You are invited to listen to the live ... access it directly at http://edge.media-server.com/m/p/mr4uxgas . A recorded replay ... of the live event and accessible at the links above ...
(Date:4/26/2016)... , April 27, 2016 Research ... "Global Molecular Diagnostics Market 2016-2020" report to their ... , ,The global molecular diagnostics market is projected to ... 2016-2020. Molecular diagnostics is a technique that ... the molecular level to detect changes in biochemical pathways. ...
Breaking Medicine Technology: